GB00BDFBVT43 - A2JLRX (XLON)
OXFORD BIOMEDICA Aktie
3,49 GBP
Aktuelle Kurse von OXFORD BIOMEDICA
Börse | Ticker | Währung | Letzter Umsatz | Kurs | Tagesveränderung | Tagesveränderung % |
---|---|---|---|---|---|---|
London |
OXB.L
|
GBX
|
20.09.2024 15:08
|
349,25 GBX
| 350,00 GBX | -0,21 % |
Performance
Tag | Woche | Monat | 3 Monate | 6 Monate | 1 Jahr | 5 Jahre |
---|---|---|---|---|---|---|
1,70 % | 3,02 % | -1,90 % | 11,23 % | 82,85 % | 29,83 % | -35,08 % |
Firmenprofil zu OXFORD BIOMEDICA Aktie
Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of cell and gene therapy products in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates various therapeutic genes. The company's products under development stage include Axo-Lenti-PD, a gene-based treatment for parkinson's disease; OXB-302, which is in pre-clinical stage for the treatment of haematological tumours; OXB-401 that is in pre-clinical stage for the treatment of liver indication; OXB-40X for liver indication; and OXB-40Y for liver indication. The company has partnerships with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Immatics, Arcellx, and Vaccines Manufacturing and Innovation Centre. The company also has a research collaboration agreement with Circularis Biotechnologies to identify novel tissue specific promoters for in vivo lentiviral gene therapy products; Virica Biotech for scaling of viral medicines; Isolere Bio provides a platform technology for tackling downstream inefficiencies in the manufacturing of biologics; and BiologIC Technologies provides novel biocomputer system for viral vector development. Oxford Biomedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.
Investierte Fonds
Folgende Fonds haben in OXFORD BIOMEDICA investiert:
Fonds | Vol. in Mio 3.188,45 | Anteil (%) 0,21 % |
Fonds | Vol. in Mio 1.198,47 | Anteil (%) 0,20 % |
Unternehmensdaten zur OXFORD BIOMEDICA Aktie
Name OXFORD BIOMEDICA
Firma Oxford Biomedica plc
Website https://www.oxb.com
Heimatbörse
London
WKN A2JLRX
ISIN GB00BDFBVT43
Wertpapierart Aktie
Sektor Healthcare
Branche Biotechnology
CEO Dr. Frank Mathias
Marktkapitalisierung 372 Mio
Land Großbritannien und Nordirland
Währung GBP
Mitarbeiter 0,7 T
Adresse Windrush Court, OX4 6LT Oxford
IPO Datum 1996-12-13
Aktien-Splits
Datum | Split |
---|---|
30.05.2018 | 1:50 |
Ticker Symbole
Name | Symbol |
---|---|
Frankfurt | OXOA.F |
London | OXB.L |
Weitere Aktien
Investoren die OXFORD BIOMEDICA halten haben auch folgende Aktien im Depot:
Die Finanzplattform goSPATZ trackt und analysiert Investitionen und Portfolios.
Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
All rights reserved © LCP GmbH 2024